Biogen Idec Inc News on Daylife

Biogen shareholder denounces CEO pay

Mon, 23 Nov 2009 15:49:41 GMT

A Biogen Idec shareholder is castigating CEO James Mullen (photo) for selling $85 million in company stock and picking up $63 million in compensation, Reuters reports. And no, the shareholder isn't Carl Icahn.
Source: FiercePharma

Receptos Completes $25M Series A Financing

Mon, 23 Nov 2009 13:41:04 GMT

SAN DIEGO -- (BUSINESS WIRE) -- Receptos, Inc. , a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing.
Source: Freshnews.com

Receptos raises $25 million through Series A financing

Mon, 23 Nov 2009 13:33:52 GMT

Receptos, Inc. , a privately held biopharmaceutical company, announced the closing of a two-tranche $25 million Series A financing.
Source: News-Medical.net

Receptos, Led By Biogen Idec Vets and Scripps Stars, Snags $25M For Drug Discovery Engine

Mon, 23 Nov 2009 08:36:55 GMT

Receptos, a San Diego-based biotech startup formed by a number of Biogen Idec veterans, has nailed down $25 million in venture capital to develop a vivid new way to look at certain protein structures on cells that it hopes will ultimately take a lot of...
Source: Xconomy

Biogen shareholder slams CEO pay, calls for measures to boost stock price

Fri, 20 Nov 2009 19:39:12 GMT

One of Biogen Idec Inc.’s largest investors is criticizing chief executive James Mullen’s compensation package and other corporate spending initiatives in an effort to goad the company into boosting its stock performance.
Source: Boston Business Journal

Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder

Fri, 20 Nov 2009 18:41:11 GMT

New York-based HealthCor Management, a hedge fund that invests in health and biotech companies, said today in a regulatory filing that Biogen (NASDAQ: BIIB) overpays CEO James Mullen, that his performance has been poor, and that the company has a...
Source: Xconomy

Biogen Idec, Inc. (Massachusetts)'s Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn???t Look So Deadly Anymore

Thu, 19 Nov 2009 16:30:28 GMT

Biogen Idec, Inc.
Source: Biospace

Rituximab hit with FDA complete response letter for leukaemia

Thu, 19 Nov 2009 16:05:01 GMT

The US FDA has issued a complete response letter to Genentech and Biogen Idec for the companies’ applications for Rituxan/MabThera (rituximab) for patients with previously untreated and previously treated chronic lymphocytic leukaemia (CLL) in...
Source: Scrip News

Quoted in 'Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial'

Mon, 19 Oct 2009 06:43:15 GMT

said in Street Insider:

rFIXFc is an example of Biogen Idec's commitment to developing innovative therapies to address significant unmet medical needs. The rFIXFc program has the potential to improve the lives of individuals with hemophilia B and we are excited about advancing the program

Photo from AP Photo

Wed, 03 Jun 2009 16:54:08 GMT

FILE - In this Oct. 11, 2007 file photo, activist investor Carl Icahn speaks at the World Business Forum in New York.

Make Money Online Trading Stock Symbol BIIB 20080318

Wed, 19 Mar 2008 09:08:16 GMT